Logged in as:
Search for Clinical Trials
Enter a drug name and click "Search" to analyze clinical trials
Example searches: Ketamine, Psilocybin, Esketamine, PCN-101, COMP360
PubMed Search
TEG 6S Search in neonates
Viscoelastic coagulation Monitor Search in neonates
FDA Regulatory Information
FDA Documents
Orange Book Information
DailyMed Information
FDA Warning Letters
Data sourced from FDA.gov, DailyMed, and FDA Orange Book. Last updated: March 2025
No Results Found
We couldn't find any FDA data for these companies. Try different company names or check your spelling.
TEG 6S Clinical Research Dashboard
Comprehensive analysis of neonatal & pediatric applications
Key Neonatal Research Findings
Critical Research Gap Identified
No TEG 6S trials include neonates or premature infants in the dataset. The youngest age group in current trials is 3 months to 18 years (NCT05874843).
Blood Collection Method
All trials use citrated blood (3.2% citric acid) and require reactivation before analysis. No small-volume protocols for neonates identified.
Neonatal Applications
Potential neonatal concerns (tiny blood volumes, different coagulation values) not addressed in any identified trials or publications.
FDA Clearance Status
TEG 6S received FDA 510(k) clearance in 2019 (K183160) with an updated cartridge in 2024. No specific neonatal clearance documented.
Search & Filter Trials
Age Range Summary
| Trial ID | Age Range | Neonatal Inclusion | Relevant Population |
|---|
TEG 6S Clinical Trials
|
Trial ID
|
Title
|
Sponsor |
Registration Date
|
Status | Age Range | Actions |
|---|
Neonatal Research Gap Analysis
Current Limitations
- No trials include neonates (<28 days) or premature infants
- Youngest cohort: 3 months to 18 years (NCT05874843)
- Blood volume constraints of neonates not addressed in any protocols
- No specific neonatal reference ranges available for TEG 6S parameters
- Citrated blood draw procedures not validated for very small volume collections
Clinical Implications
- Premature and newborn infants have distinct coagulation profiles compared to older children and adults
- Standard blood collection volumes may be excessive for neonates with limited blood volume
- Interpretation of TEG 6S results in neonates would require specific reference ranges
- Risk/benefit ratio of TEG 6S testing in neonates has not been formally assessed
Research Opportunities
- Validation study of TEG 6S in neonatal populations with age-appropriate reference ranges
- Development of micro-sampling techniques compatible with TEG 6S cartridges
- Comparison of citrated vs. non-citrated samples in neonatal blood
- Assessment of minimal blood volume requirements for valid results
Overall Drug Success Rates
Treatment Efficacy Comparison Across Trials
This visualization combines data from all trials to show overall effectiveness of treatments. Higher values indicate better outcomes relative to placebo.
Response Rate Distribution
Percentage of patients who responded to treatment
Remission Rate Distribution
Percentage of patients who achieved remission
Statistical Summary by Drug
| Drug | Trials | Total Patients | Avg. Effect Size | Response Rate | Remission Rate |
|---|
Results Overview
Collated Trial Outcomes
Overall Treatment Effect Distribution
Phase Comparison
Compare effect sizes across different clinical trial phases. Higher values indicate better outcomes.
Comparative Phase Performance
Direct comparison of phase-specific effect sizes with confidence intervals.
Statistical Summary
| Phase | Trials | Mean Effect | Standard Deviation | 95% CI | p-value |
|---|